RTTNews | Mar 23, 2021 08:21AM EDT

08:21 Tuesday, March 23, 2021 (RTTNews.com) - Hoth Therapeutics, Inc. (HOTH) reported in vitro data showing SARS-CoV-2 antiviral activity for its lead peptide candidate for HT-002, a therapeutic targeted for the treatment of COVID-19. The company said the data supports that HT-002 has the potential to be developed as a novel therapeutic to both prevent and treat COVID-19. The company plans to pursue further preclinical animal studies.

"We are encouraged by these extremely positive in vitro results supporting that HT-002's novel peptide could provide substantial antiviral activity against SARS-CoV-2," said Stefanie Johns, Chief Scientific Officer of Hoth Therapeutics.

Shares of Hoth Therapeutics were up nearly 60% in pre-market trade on Tuesday.

Read the original article on RTTNews ( https://www.rttnews.com/3179477/hoth-extremely-positive-in-vitro-data-supports-ht-002-s-antiviral-activity-against-sars-cov-2.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved